HOME > TOP STORIES

TOP STORIES

ORGANIZATION Funding Disclosures by 5 More FPMAJ Trade Groups to Get Underway in FY2014

March 27, 2014
BUSINESS Major Generic Prices to Hover around 50% of Original Drug Prices in Their 1st Revision: Jiho

March 26, 2014
BUSINESS Novartis Will Not Sell Rasilamlo Blood Pressure Drug in Japan

March 26, 2014
REGULATORY MHLW to Disclose Names of Wholesalers Abusing Penalty for Low Price-Settlement Rates

March 25, 2014
ACADEMIA Experts Disagree over Full-Introduction of GCP at JCS Meeting

March 24, 2014
ORGANIZATION JPMA Urges Takeda to Improve Promotion Regime over CASE-J

March 24, 2014
REGULATORY MHLW to Set Rules on OTC Switching of Diagnostics This Year

March 20, 2014
BUSINESS Eli Lilly Japan Sales Up 9% in 2013

March 19, 2014
ACADEMIA Trial Investigators Brush Aside Concerns over CASE-J in US Journal

March 18, 2014
ACADEMIA University of Tokyo Admits Patient Information on SIGN Trial Leaked to Novartis

March 17, 2014
REGULATORY Eligibility for Key Pricing Premium Up for Discussion: Govt

March 17, 2014
BUSINESS LEO Pharma to Carefully Ponder When to Begin Solo Marketing in Japan: Local Head

March 14, 2014
BUSINESS Otsuka to Disclose Patient-Level Clinical Trial Data

March 13, 2014
BUSINESS AstraZeneca, Osaka University Aim to Resurrect Ditched Drug Candidates

March 13, 2014
ORGANIZATION PhRMA “Disappointed” by Rule Changes for Foreign Price Adjustments: New Japan Committee Chair

March 12, 2014
REGULATORY Revisions of Prefectural Disaster Plans for Drug Distribution Almost Complete

March 11, 2014
BUSINESS Pfizer Japan Logs 1.2% Sales Increase in FY2013

March 10, 2014
BUSINESS Takeda Submits NDA for Once-Weekly DPP-4 Inhibitor Trelagliptin

March 10, 2014
ORGANIZATION FPMAJ Generic Guidelines Urge Makers to Create “Stable Supply” Officer Post

March 7, 2014
BUSINESS 28% of Mainstays to Face New Price Cuts for Long-Listed Drugs: Jiho Survey

March 7, 2014

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…